Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Brain–computer interfaces are expanding from functional to recreational applications, as evidenced by a study in which a person with tetraplegia controlled a recreational virtual drone, but their clinical utility is still uncertain.
A study detected hidden cancers in almost half of all pregnant people who were referred for cancer screening following an abnormal or unreportable prenatal blood test result.
In an analysis of long-term safety events in 783 patients treated with T cell therapy in 38 trials, 2.3% of patients developed second primary malignancies, and vector integration analyses revealed no pathological insertions.
A finger-based brain–computer interface was developed for a person with tetraplegia to allow him to fly a virtual quadcopter, an innovation that can lead to improved social connectedness, recreation and a sense of enablement.
An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medications, such as sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors.
This Review explores the state-of-the-art applications of artificial intelligence in small-molecule drug development, from target identification and drug synthesis up to clinical trial design and conduct.
Obesity is associated with many life-threatening comorbidities. Its heterogeneous risk profile makes the prevention of obesity and its pathogenic consequences challenging. In this study, the heterogeneous relationships between body mass index and ten cardiovascular risk markers were quantified using machine learning, from which powerful clinical prediction models were developed and validated.
A comprehensive longitudinal analysis of individuals with preclinical Huntington’s disease identifies biomarkers of neurodegeneration and somatic expansion in blood DNA, detectable years before symptom onset.
In this phase 2 basket trial, patients with heavily pretreated HER2-mutated metastatic breast cancer received the small-molecule HER2 inhibitor tucatinib and anti-HER2 trastuzumab, leading to encouraging clinical response rates.
This flagship study from the European Solve-Rare Diseases Consortium presents a diagnostic framework including bioinformatic analysis of clinical, pedigree and genomic data coupled with expert panel review, leading to 500 new diagnoses in a cohort of 6,000 families with suspected rare diseases.
According to preclinical studies and a retrospective clinical analysis, the menstrual cycle may influence the breast cancer response to neoadjuvant chemotherapy — suggesting that treatment could be timed for optimal outcomes.
In a case series of five children with treatment-refractory neuroblastoma, it was feasible to manufacture and administer donor-derived GD2-specific CAR T cells and clinical responses were seen in four patients.
An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion isolate.
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatment option for an infection with no approved therapies.
